Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2056-9920
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study ; volume:7 ; number:1 ; day:16 ; month:2 ; year:2021 ; pages:1-10 ; date:12.2021
International Journal of Retina and Vitreous ; 7, Heft 1 (16.2.2021), 1-10, 12.2021
- Urheber
-
Minturn, Robert J.
Bracha, Peter
Klein, Margaret J.
Chhablani, Jay
Harless, Ashley M.
Maturi, Raj K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40942-021-00281-0
- URN
-
urn:nbn:de:101:1-2021040520565570180901
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Minturn, Robert J.
- Bracha, Peter
- Klein, Margaret J.
- Chhablani, Jay
- Harless, Ashley M.
- Maturi, Raj K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
Age-related macular degeneration
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
Age-related macular degeneration
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
Age-related macular degeneration
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05